BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16932322)

  • 1. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders.
    Savage MO; Attie KM; David A; Metherell LA; Clark AJ; Camacho-Hübner C
    Nat Clin Pract Endocrinol Metab; 2006 Jul; 2(7):395-407. PubMed ID: 16932322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and therapeutic advances in growth hormone insensitivity.
    David A; Metherell LA; Clark AJ; Camacho-Hübner C; Savage MO
    Endocrinol Metab Clin North Am; 2005 Sep; 34(3):581-95, viii. PubMed ID: 16085161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short stature and decreased insulin-like growth factor I (IGF-I)/growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor.
    Meyer S; Ipek M; Keth A; Minnemann T; von Mach MA; Weise A; Ittner JR; Nawroth PP; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Kann PH; ;
    Growth Horm IGF Res; 2007 Aug; 17(4):307-14. PubMed ID: 17462934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A half-century of studies of growth hormone insensitivity/Laron syndrome: A historical perspective.
    Rosenbloom AL
    Growth Horm IGF Res; 2016 Jun; 28():46-50. PubMed ID: 26276451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and growth hormone receptor gene mutations of patients with Laron syndrome from a Chinese family.
    Ying YQ; Wei H; Cao LZ; Lu JJ; Luo XP
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug; 9(4):335-8. PubMed ID: 17706034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
    Laron Z
    Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
    Ranke MB
    Trends Endocrinol Metab; 2005; 16(4):190-7. PubMed ID: 15860416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New molecular mechanisms of growth hormone insensitivity].
    Edouard T; Raynal P; Yart A; Conte-Auriol F; Salles JP; Tauber M
    Arch Pediatr; 2008 Feb; 15(2):179-88. PubMed ID: 18207712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic spectrum and responses to recombinant human IGF1 (rhIGF1) therapy in patients with homozygous intronic pseudoexon growth hormone receptor mutation.
    Chatterjee S; Shapiro L; Rose SJ; Mushtaq T; Clayton PE; Ten SB; Bhangoo A; Kumbattae U; Dias R; Savage MO; Metherell LA; Storr HL
    Eur J Endocrinol; 2018 May; 178(5):481-489. PubMed ID: 29500309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel GHR intronic variant, c.266+83G>T , activates a cryptic 5' splice site causing severe GHR deficiency and classical GH insensitivity syndrome.
    Feigerlova E; Swinyard M; Derr MA; Farnsworth J; Andrew SF; Rosenfeld RG; Hwa V
    Horm Res Paediatr; 2013; 80(6):397-405. PubMed ID: 24296660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel exonic GHR splicing mutation (c.784G > C) in a patient with classical growth hormone insensitivity syndrome.
    Akıncı A; Rosenfeld RG; Hwa V
    Horm Res Paediatr; 2013; 79(1):32-8. PubMed ID: 23006617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel growth hormone receptor gene deletion mutation in a patient with primary growth hormone insensitivity syndrome (Laron syndrome).
    Yamamoto H; Kouhara H; Iida K; Chihara K; Kasayama S
    Growth Horm IGF Res; 2008 Apr; 18(2):136-42. PubMed ID: 17728167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Competencies for Effective Pediatric Endocrine Nursing Practice.
    Davies K; Dwyer AA
    J Pediatr Nurs; 2019; 48():127-128. PubMed ID: 31409498
    [No Abstract]   [Full Text] [Related]  

  • 14. [Laron type dwarfism].
    Okimura Y
    Nihon Rinsho; 2006 May; Suppl 1():94-7. PubMed ID: 16776102
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic applications of the insulin-like growth factors.
    Savage MO; Camacho-Hübner C; Dunger DB
    Growth Horm IGF Res; 2004 Aug; 14(4):301-8. PubMed ID: 15231299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics and disease. Growth defect blocks cancer and diabetes.
    Leslie M
    Science; 2011 Feb; 331(6019):837. PubMed ID: 21330503
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapy with recombinant human IGF-1 for children with primary insulin-like growth factor-I deficiency.
    Backeljauw P
    Growth Horm IGF Res; 2020 Apr; 51():22-26. PubMed ID: 31982729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone insensitivity: diagnostic and therapeutic approaches.
    Kurtoğlu S; Hatipoglu N
    J Endocrinol Invest; 2016 Jan; 39(1):19-28. PubMed ID: 26062520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome).
    Laron Z
    J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():231-49. PubMed ID: 10698588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intellectual capacity of patients with Laron syndrome (LS) differs with various molecular defects of the growth hormone receptor gene. Correlation with CNS abnormalities.
    Shevah O; Kornreich L; Galatzer A; Laron Z
    Horm Metab Res; 2005 Dec; 37(12):757-60. PubMed ID: 16372230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.